Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...

7 An estimated one million people develop shingles annually in the US. 8 About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in ...

Please see full Prescribing Information for AREXVY. About SHINGRIX(Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles ...

Please see full Prescribing Information for AREXVY. About SHINGRIX(Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

and Shingrix (zoster vaccine recombinant, adjuvanted). The open-label study included 530 adults aged 50 years and older who were randomly assigned to receive either the first dose of Shingrix with ...